Please login to the form below

Vimpat

This page shows the latest Vimpat news and features for those working in and with pharma, biotech and healthcare.

UCB bags FDA approval for epilepsy drug Briviact

Belgium-headquartered UCB is already an established player in epilepsy with drugs such as Vimpat (lacosamide) and Keppra (levetiracetam), which is off-patent in most major markets. ... Vimpat added another 495m.

Latest news

UCB wins European approval for epilepsy drug Briviact

The drug adds to an epilepsy treatment portfolio at UCB currently represented by Vimpat (lacosamide) - with sales of 495m in the first nine months of 2015 - along with Keppra (levetiracetam) which
UCB boosted by core medicines growth

Revenue was boosted by its core product range, with Crohn's disease and psoriatic arthritis treatment Cimzia (certolizumab pegol); epilepsy medicine Vimpat (lacosamide) and Parkinson's disease and restless leg syndrome ... Sales of Vimpat increased by 15%
UCB submits brivaracetam for use in epilepsy

The company has since turned to other drugs in its epilepsy portfolio, including Vimpat (lacosamide). ... At the end of last year UCB announced a partnership with Daiichi Sankyo to bring Vimpat to Japan.
New UCB CEO Jean-Christophe Tellier expands his executive team

Hands new roles to Emmanuel Caeymaex, Bharat Tewarie and Jeff Wren
UCB partners with Daiichi to bring epilepsy drug to Japan

UCB partners with Daiichi to bring epilepsy drug to Japan. Companies partner on expanding market for Vimpat. ... Vimpat is an important drug for UCB as it looks to overcome the loss in revenue due to the loss of patent protection for older anti-epileptic

More from news
Approximately 8 fully matching, plus 14 partially matching documents found.

Latest Intelligence

Pharma deals during November 2013

Certainly the good performances from key products such as Cimzia, Vimpat and Neupro may well appeal to those companies feeling a little pipeline bereft.
VIDEO interview: Neil Weir, UCB

For UCB, this notion is especially important considering its focus on severe diseases, including the recent launches of Cimzia (certolizumab pegol) for rheumatoid arthritis and Crohn's disease; Vimpat (lacosamide) for ... As for the future of the company,
Interview with Roch Doliveux, UCB

It is the same with Vimpat. Peak sales were once 350m; now, estimates are at least 1.2bn. ... Vimpat treats a subset of epilepsy, partial onset seizures. One in three patients has this refractory type of seizure.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Systematic Review Lead- London: Negotiable

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Healthcare PR Director: £100, 000 – £120, 000 benefits

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Senior Training Manager - Surrey: Competitive Salary &Bonus

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Market Access Consultant - Greater Manchester: Negotiable

Senior Account Manager – Healthcare Advertising: Salary TBC

Senior Writer, Healthcare Advertising, London: Excellent package

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Medical Writer - Creative and Scientific Projects: DOE

Account Director or Senior Account Director: Salary TBC

Account Manager: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

The gene therapy revolution: Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...